J. Goldman & CO LP Replimune Group, Inc. Call Options Transaction History

J. Goldman & CO LP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$8.09 - $11.23 $97,889 - $135,883	12,100 New	12,100 $132,000
Q3 2023 Nov 14, 2023	SELL	$15.96 - $22.18 $604,884 - $840,622	-37,900 Reduced 41.24%	54,000 $923,000
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $1.44 Million - $2.21 Million	91,900 New	91,900 $2.13 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $709M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.